Correction to: Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies (Targeted Oncology, (2023), 18, 1, (9-24), 10.1007/s11523-022-00941-7)
Popat S., Ahn M.J., Ekman S., Leighl N.B., Ramalingam S.S., Reungwetwattana T., Siva S., Tsuboi M., Wu Y.L., Yang J.C.H. Correction to: Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies (Targeted Oncology, (2023), 18, 1, (9-24), 10.1007/s11523-022-00941-7). Targeted Oncology Vol.18 No.2 (2023) , 311. doi:10.1007/s11523-023-00947-9 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/81644
Title
Correction to: Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies (Targeted Oncology, (2023), 18, 1, (9-24), 10.1007/s11523-022-00941-7)
